196 related articles for article (PubMed ID: 37720425)
1. Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: a case report.
Kudelka MR; Abou-Alfa GK; O'Reilly EM; Foote MB; Sirohi B; Elias R; Shamseddine A; Paroder V; Moussa AM; Cohen P; Ganesh K
J Gastrointest Oncol; 2023 Aug; 14(4):1878-1886. PubMed ID: 37720425
[TBL] [Abstract][Full Text] [Related]
2. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
3. First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor.
Nath E; Sawyer MB; Choy J
Case Rep Oncol; 2020; 13(3):1454-1462. PubMed ID: 33442370
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
5. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report.
Gerson JN; Witteles RM; Chang DT; Beygui RE; Iagaru AH; Kunz PL
Pancreas; 2017; 46(10):1381-1385. PubMed ID: 29040196
[TBL] [Abstract][Full Text] [Related]
6. Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
Dero I; De Pauw M; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Peeters M
Acta Gastroenterol Belg; 2009; 72(1):34-8. PubMed ID: 19402369
[TBL] [Abstract][Full Text] [Related]
7. Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior.
Capuano F; Grami O; Pugliese L; Paulli M; Pietrabissa A; Solcia E; Vanoli A
Endocr Pathol; 2018 Dec; 29(4):369-373. PubMed ID: 30076568
[TBL] [Abstract][Full Text] [Related]
8. High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report.
Van Fraeyenhove F; Meireson N; Terriere L; Willemsen P; Kunnen J; Mattelaer C; Van Acker F; Schrijvers D
Case Rep Oncol; 2014 Jan; 7(1):155-63. PubMed ID: 24707264
[TBL] [Abstract][Full Text] [Related]
9. Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management.
Jin C; Sharma AN; Thevakumar B; Majid M; Al Chalaby S; Takahashi N; Tanious A; Arockiam AD; Beri N; Amsterdam EA
Cardiology; 2021; 146(1):65-73. PubMed ID: 33070143
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
12. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
13. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
14. [The ectopic ACTH syndrome].
Penezić Z; Savić S; Vujović S; Tatić S; Ercegovac M; Drezgićc M
Srp Arh Celok Lek; 2004; 132(1-2):28-32. PubMed ID: 15227962
[TBL] [Abstract][Full Text] [Related]
15. Four decades of experience with carcinoid heart disease: An analysis of 84 patients.
Levy S; Korse CE; de Groot ACA; Meijer RCA; Tesselaar MET; Valk GD
J Neuroendocrinol; 2022 Oct; 34(10):e13199. PubMed ID: 36256859
[TBL] [Abstract][Full Text] [Related]
16. Carcinoid heart disease.
Gustafsson BI; Hauso O; Drozdov I; Kidd M; Modlin IM
Int J Cardiol; 2008 Oct; 129(3):318-24. PubMed ID: 18571250
[TBL] [Abstract][Full Text] [Related]
17. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
18. Carcinoid Heart Disease-Induced Right-Sided Heart Failure as a Culprit for Significant Ascites.
Huang Y; Park DY; Almoghrabi A; Nanna MG
Case Rep Gastroenterol; 2023; 17(1):172-177. PubMed ID: 36974060
[TBL] [Abstract][Full Text] [Related]
19. Late-stage diagnosis of carcinoid heart disease due to lack of access to health care.
Sharma A; Fierro ME; Pak S; Thallapureddy K; Awobajo M; Hui D; Otchere P
Cardiooncology; 2023 Jun; 9(1):28. PubMed ID: 37277819
[TBL] [Abstract][Full Text] [Related]
20. Update in carcinoid heart disease - the heart of the matter.
Oleinikov K; Korach A; Planer D; Gilon D; Grozinsky-Glasberg S
Rev Endocr Metab Disord; 2021 Sep; 22(3):553-561. PubMed ID: 33443717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
